Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 6 of 6

References

256 sources

  1. Abraxane prescribing information (2020) (opens in a new tab)
  2. Afinitor prescribing information (2026) (opens in a new tab)
  3. Allen (2010) (opens in a new tab)
  4. Allison et al. (2020) (opens in a new tab)
  5. American Cancer Society Breast Cancer Facts and Figures (2024) (opens in a new tab)
  6. American Cancer Society Cancer Facts and Figures (2026) (opens in a new tab)
  7. American Cancer Society Key Statistics for Breast Cancer (2026) (opens in a new tab)
  8. Andrade et al. (2024) (opens in a new tab)
  9. André et al. (2019) (opens in a new tab)
  10. André et al. (2021) (opens in a new tab)
  11. Aromasin prescribing information (2024) (opens in a new tab)
  12. AstraZeneca SERENA-4 update announcement (2026) (opens in a new tab)
  13. AstraZeneca Truqap blister pack availability notice (2024) (opens in a new tab)
  14. Atre et al. (2024) (opens in a new tab)
  15. Bardia et al. (2024a) (opens in a new tab)
  16. Bardia et al. (2024b) (opens in a new tab)
  17. Bardia et al. (2025) (opens in a new tab)
  18. Barratt et al. (2026) (opens in a new tab)
  19. Baselga et al. (2012) (opens in a new tab)
  20. Behan et al. (2025) (opens in a new tab)
  21. Bello et al. (2026) (opens in a new tab)
  22. Benvenuti et al. (2023) (opens in a new tab)
  23. Bhave et al. (2024) (opens in a new tab)
  24. Bidard et al. (2022) (opens in a new tab)
  25. Bidard et al. (2025) (opens in a new tab)
  26. Borges et al. (2023a) (opens in a new tab)
  27. Borges et al. (2023b) (opens in a new tab)
  28. Borges et al. (2024a) (opens in a new tab)
  29. Borges et al. (2024b) (opens in a new tab)
  30. Bramley et al. (2016) (opens in a new tab)
  31. Brett et al. (2021) (opens in a new tab)
  32. Brufsky et al. (2024) (opens in a new tab)
  33. Burstein et al. (2021) (opens in a new tab)
  34. Burstein et al. (2023) (opens in a new tab)
  35. Burstein et al. (2024) (opens in a new tab)
  36. Cabel et al. (2026) (opens in a new tab)
  37. Cadirov et al. (2025) (opens in a new tab)
  38. CADTH capivasertib reimbursement recommendation (2024) (opens in a new tab)
  39. Campone et al. (2025) (opens in a new tab)
  40. Cardoso et al. (2024) (opens in a new tab)
  41. Cardoso et al. (2026) (opens in a new tab)
  42. Celcuity Form 10-Q (2026) (opens in a new tab)
  43. Chan et al. (2023a) (opens in a new tab)
  44. Chan et al. (2023b) (opens in a new tab)
  45. Chan et al. (2023c) (opens in a new tab)
  46. Chan et al. (2024) (opens in a new tab)
  47. Chandarlapaty et al. (2016) (opens in a new tab)
  48. Ciruelos et al. (2021) (opens in a new tab)
  49. Cleeland et al. (2014) (opens in a new tab)
  50. ClinicalTrials.gov NCT04505826 (opens in a new tab)
  51. ClinicalTrials.gov NCT04505826 results (opens in a new tab)
  52. ClinicalTrials.gov NCT05266105 (opens in a new tab)
  53. ClinicalTrials.gov NCT05508906 (opens in a new tab)
  54. ClinicalTrials.gov NCT06016738 (opens in a new tab)
  55. ClinicalTrials.gov NCT07085767 (opens in a new tab)
  56. CMS ADLT list (2026) (opens in a new tab)
  57. CMS Clinical Laboratory Fee Schedule (2026) (opens in a new tab)
  58. CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026) (opens in a new tab)
  59. CMS Enhancing Oncology Model FAQ (2026) (opens in a new tab)
  60. CMS National Coverage Determination 90.2 (2020) (opens in a new tab)
  61. CMS Quality ID 047 (2026) (opens in a new tab)
  62. CMS Quality ID 143 (2026) (opens in a new tab)
  63. CMS Quality ID 144 (2026) (opens in a new tab)
  64. CMS Quality ID 453 (2026) (opens in a new tab)
  65. CMS Quality ID 457 (2026) (opens in a new tab)
  66. Comerford et al. (2025) (opens in a new tab)
  67. Cong et al. (2022) (opens in a new tab)
  68. Cortes et al. (2011) (opens in a new tab)
  69. Curigliano et al. (2026a) (opens in a new tab)
  70. Curigliano et al. (2026b) (opens in a new tab)
  71. Daily et al. (2021) (opens in a new tab)
  72. Datroway prescribing information (2026) (opens in a new tab)
  73. de Azambuja et al. (2026) (opens in a new tab)
  74. Dilawari et al. (2024) (opens in a new tab)
  75. Dilawari et al. (2025) (opens in a new tab)
  76. Eli Lilly and Company Inluriyo WAC disclosure (2025) (opens in a new tab)
  77. Enhertu prescribing information (2026) (opens in a new tab)
  78. Etcamah prescribing information (2026) (opens in a new tab)
  79. EU CTIS 2023-505871-63-00 (opens in a new tab)
  80. Faslodex prescribing information (2021) (opens in a new tab)
  81. FDA (2018) (opens in a new tab)
  82. FDA camizestrant approval notice (2026) (opens in a new tab)
  83. FDA gedatolisib approval notice (2026) (opens in a new tab)
  84. FDA Guardant360 CDx SSED S021 (2025) (opens in a new tab)
  85. FDA imlunestrant and abemaciclib approval notice (2026) (opens in a new tab)
  86. FDA imlunestrant approval notice (2025) (opens in a new tab)
  87. FDA vepdegestrant approval notice (2026) (opens in a new tab)
  88. Flavin et al. (2026) (opens in a new tab)
  89. Franklin et al. (2024) (opens in a new tab)
  90. Fribbens et al. (2016) (opens in a new tab)
  91. Gallicchio et al. (2022) (opens in a new tab)
  92. Gauthier et al. (2018) (opens in a new tab)
  93. Giaquinto et al. (2024) (opens in a new tab)
  94. Giuliano et al. (2019) (opens in a new tab)
  95. Gogate et al. (2021) (opens in a new tab)
  96. Goyal et al. (2019) (opens in a new tab)
  97. Goyal et al. (2021) (opens in a new tab)
  98. Gradishar et al. (2026) (opens in a new tab)
  99. Greer et al. (2020) (opens in a new tab)
  100. Gupta et al. (2025) (opens in a new tab)
  101. Halaven prescribing information (2022) (opens in a new tab)
  102. Hamilton et al. (2022) (opens in a new tab)
  103. Hamilton et al. (2025) (opens in a new tab)
  104. Hanker et al. (2020) (opens in a new tab)
  105. Hao et al. (2016) (opens in a new tab)
  106. Henry et al. (2022) (opens in a new tab)
  107. Howlader et al. (2018) (opens in a new tab)
  108. Hurvitz et al. (2026) (opens in a new tab)
  109. Inluriyo prescribing information (2026) (opens in a new tab)
  110. International Agency for Research on Cancer GLOBOCAN breast fact sheet (2026) (opens in a new tab)
  111. Irvin et al. (2011) (opens in a new tab)
  112. Itovebi prescribing information (2026) (opens in a new tab)
  113. Jaber Chehayeb et al. (2022) (opens in a new tab)
  114. Jeselsohn et al. (2015) (opens in a new tab)
  115. Jhaveri et al. (2025a) (opens in a new tab)
  116. Jhaveri et al. (2025b) (opens in a new tab)
  117. Jhaveri et al. (2026a) (opens in a new tab)
  118. Jhaveri et al. (2026b) (opens in a new tab)
  119. Kalinsky et al. (2023) (opens in a new tab)
  120. Kalinsky et al. (2025) (opens in a new tab)
  121. Kalinsky et al. (2026) (opens in a new tab)
  122. Kamal et al. (2017) (opens in a new tab)
  123. Kashiwa et al. (2026) (opens in a new tab)
  124. Kaufman et al. (2015) (opens in a new tab)
  125. Kuksis et al. (2021) (opens in a new tab)
  126. Lambert et al. (2024) (opens in a new tab)
  127. Lang et al. (2024) (opens in a new tab)
  128. Liang et al. (2026) (opens in a new tab)
  129. Liao et al. (2026) (opens in a new tab)
  130. Lin et al. (2023) (opens in a new tab)
  131. Lin et al. (2024) (opens in a new tab)
  132. Lin et al. (2025a) (opens in a new tab)
  133. Lin et al. (2025b) (opens in a new tab)
  134. Litton et al. (2018) (opens in a new tab)
  135. Litton et al. (2020) (opens in a new tab)
  136. Lloyd et al. (2006) (opens in a new tab)
  137. Lloyd et al. (2022) (opens in a new tab)
  138. Lloyd et al. (2024) (opens in a new tab)
  139. Lloyd et al. (2026a) (opens in a new tab)
  140. Lloyd et al. (2026b) (opens in a new tab)
  141. Lord et al. (2022) (opens in a new tab)
  142. Lynparza prescribing information (2025) (opens in a new tab)
  143. Mariotto et al. (2017) (opens in a new tab)
  144. Mariotto et al. (2020) (opens in a new tab)
  145. Martin et al. (2022) (opens in a new tab)
  146. Mayer et al. (2024) (opens in a new tab)
  147. Mayer et al. (2026a) (opens in a new tab)
  148. Mayer et al. (2026b) (opens in a new tab)
  149. Meisel et al. (2026) (opens in a new tab)
  150. Mertz et al. (2022) (opens in a new tab)
  151. Modi et al. (2022) (opens in a new tab)
  152. Modi et al. (2025) (opens in a new tab)
  153. Moy et al. (2021) (opens in a new tab)
  154. Moy et al. (2022) (opens in a new tab)
  155. Moy et al. (2023) (opens in a new tab)
  156. National Cancer Institute Breast Cancer Treatment PDQ (2025) (opens in a new tab)
  157. National Cancer Institute Metastatic Cancer (2026) (opens in a new tab)
  158. NCI Thesaurus (2026) (opens in a new tab)
  159. Neuss et al. (2016) (opens in a new tab)
  160. Ng et al. (2025) (opens in a new tab)
  161. Nguyen and Mital (2025) (opens in a new tab)
  162. Nguyen and Mital (2026) (opens in a new tab)
  163. NICE TA1036 committee discussion (2025) (opens in a new tab)
  164. NICE TA1036 recommendation (2025) (opens in a new tab)
  165. NICE TA1168 terminated appraisal (2026) (opens in a new tab)
  166. Nsubayi et al. (2026) (opens in a new tab)
  167. Okeke et al. (2025) (opens in a new tab)
  168. Olema Oncology AACR 2026 preclinical data announcement (2026) (opens in a new tab)
  169. Olema Oncology corporate name change announcement (2026) (opens in a new tab)
  170. Olema Oncology corporate presentation (2026) (opens in a new tab)
  171. Olema Oncology dose selection announcement (2025) (opens in a new tab)
  172. Olema Oncology ESMO 2025 ribociclib results announcement (2025) (opens in a new tab)
  173. Olema Oncology Fast Track designation announcement (2022) (opens in a new tab)
  174. Olema Oncology first quarter 2026 results announcement (2026) (opens in a new tab)
  175. Olema Oncology Form 10-K (2026) (opens in a new tab)
  176. Olema Oncology Form 10-Q (2026) (opens in a new tab)
  177. Olema Oncology fourth quarter and full year 2025 results announcement (2026) (opens in a new tab)
  178. Olema Oncology Novartis collaboration expansion announcement (2023) (opens in a new tab)
  179. Olema Oncology Novartis OPERA-02 agreement announcement (2024) (opens in a new tab)
  180. Olema Oncology Pfizer atirmociclib agreement announcement (2025) (opens in a new tab)
  181. Olema Oncology phase 2 monotherapy results announcement (2023) (opens in a new tab)
  182. Olema Oncology SABCS 2023 combination results announcement (2023) (opens in a new tab)
  183. Olema Oncology SABCS 2024 announcement (2024) (opens in a new tab)
  184. Olema Oncology SABCS 2026 presentations announcement (2026) (opens in a new tab)
  185. Olema Oncology second quarter 2025 results announcement (2025) (opens in a new tab)
  186. Olema Oncology second quarter 2026 results announcement (2026) (opens in a new tab)
  187. Olema Oncology third quarter 2025 results announcement (2025) (opens in a new tab)
  188. Olema Oncology third quarter 2026 results announcement (2026) (opens in a new tab)
  189. Oliveira et al. (2024a) (opens in a new tab)
  190. Oliveira et al. (2024b) (opens in a new tab)
  191. OP-1250-001 protocol (2022) (opens in a new tab)
  192. OP-1250-001 statistical analysis plan (2024) (opens in a new tab)
  193. Orserdu prescribing information (2026) (opens in a new tab)
  194. Pan et al. (2017) (opens in a new tab)
  195. Parisian et al. (2024) (opens in a new tab)
  196. Patel et al. (2021) (opens in a new tab)
  197. Pezzolato et al. (2023) (opens in a new tab)
  198. Piccart et al. (2014) (opens in a new tab)
  199. Piqray prescribing information (2026) (opens in a new tab)
  200. Pistilli et al. (2024) (opens in a new tab)
  201. Pistilli et al. (2025) (opens in a new tab)
  202. Pistilli et al. (2026a) (opens in a new tab)
  203. Pistilli et al. (2026b) (opens in a new tab)
  204. Revtorpyk prescribing information (2026) (opens in a new tab)
  205. Reyes et al. (2019) (opens in a new tab)
  206. Robson et al. (2017) (opens in a new tab)
  207. Robson et al. (2019) (opens in a new tab)
  208. Roche giredestrant New Drug Application acceptance announcement (2026) (opens in a new tab)
  209. Rocque et al. (2020) (opens in a new tab)
  210. Rocque et al. (2025) (opens in a new tab)
  211. Rosenzweig et al. (2019) (opens in a new tab)
  212. Royce et al. (2025) (opens in a new tab)
  213. Rugo et al. (2022) (opens in a new tab)
  214. Rugo et al. (2023) (opens in a new tab)
  215. Rugo et al. (2024) (opens in a new tab)
  216. Rugo et al. (2025) (opens in a new tab)
  217. Rugo et al. (2026) (opens in a new tab)
  218. Sammons et al. (2025) (opens in a new tab)
  219. Schiavon et al. (2015) (opens in a new tab)
  220. SEER Cancer Stat Facts Female Breast Cancer (2026) (opens in a new tab)
  221. SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026) (opens in a new tab)
  222. Shah et al. (2024) (opens in a new tab)
  223. Siegel et al. (2024) (opens in a new tab)
  224. Sorensen et al. (2012) (opens in a new tab)
  225. Sun et al. (2025) (opens in a new tab)
  226. Sung et al. (2026) (opens in a new tab)
  227. Talzenna prescribing information (2026) (opens in a new tab)
  228. Tolaney et al. (2025) (opens in a new tab)
  229. Tolaney et al. (2026) (opens in a new tab)
  230. Tolosa et al. (2026) (opens in a new tab)
  231. Toy et al. (2013) (opens in a new tab)
  232. Trodelvy prescribing information (2026) (opens in a new tab)
  233. Truqap prescribing information (2026) (opens in a new tab)
  234. Tung et al. (2020) (opens in a new tab)
  235. Turner et al. (2023) (opens in a new tab)
  236. Turner et al. (2024) (opens in a new tab)
  237. Twelves et al. (2014) (opens in a new tab)
  238. Van Poznak et al. (2017) (opens in a new tab)
  239. Veppanu prescribing information (2026) (opens in a new tab)
  240. Vermont Attorney General Orserdu report (2023) (opens in a new tab)
  241. Verzenio prescribing information (2026) (opens in a new tab)
  242. Wan et al. (2013) (opens in a new tab)
  243. Waters et al. (2024) (opens in a new tab)
  244. Wheeler et al. (2023) (opens in a new tab)
  245. WHO Proposed INN List 128 (2022) (opens in a new tab)
  246. WHO Recommended INN List 90 (2023) (opens in a new tab)
  247. Will et al. (2023) (opens in a new tab)
  248. Wolff et al. (2023) (opens in a new tab)
  249. Wood et al. (2017) (opens in a new tab)
  250. Wortelboer et al. (2025) (opens in a new tab)
  251. Wortelboer et al. (2026) (opens in a new tab)
  252. Wu et al. (2023) (opens in a new tab)
  253. Xeloda prescribing information (2025) (opens in a new tab)
  254. Yin et al. (2026) (opens in a new tab)
  255. Zeng et al. (2023) (opens in a new tab)
  256. Zhang et al. (2018) (opens in a new tab)